- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06145555
Stabilisation psychologique aiguë du sommeil pour les patients hospitalisés pour dépression
Disturbed sleep occurs in almost all patients in psychiatric inpatient care, and although it is well known that comorbid sleep disorders in depression often persist after treatment of depression and also increase the risk of new depressive episodes, the availability of effective, evidence-based treatments for sleep disorders in hospitalised patients is very limited.
The overall goal of the current project is to translate, adapt and evaluate an acute psychological sleep treatment based on cognitive behavioural therapy for insomnia (CBT-I) for patients hospitalized with depression and comorbid sleep problems in the specialized psychiatric inpatient care in the Stockholm Region. The main hypothesis for the study is that acute psychological sleep stabilization (APS) reduces self-reported sleep complains compared to care as usual reinforced with sleep hygiene advice, and secondary hypotheses are that APS also leads to reduced depressive symptoms and earlier discharge.
The project includes a pilot study, which will be followed by a randomized, controlled trial of APS compared to care as usual with structured sleep hygiene (minimal active control) and treatment effect is evaluated every three days during the hospital stay and 1,2,4 and 12 weeks after randomization. APS will be performed by existing staff in the department with the support of a psychologist.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Stockholm, Suède
- Psykiatri Sydväst, Karolinska Hospital Huddinge
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Admitted to the psychiatric inpatient care (Psykiatri Sydväst)
- Depressive symptoms / confirmed depressive episode (uni- or bipolar)
- Reports or is observed to have sleep problems in the form of insomnia, hypersomnia or delayed circadian phase
- Knowledge of Swedish or English that is deemed sufficient to undergo the treatment
- Consent to be included in the study and is judged to have understood what the study entails (care according to the Compulsory Psychiatric Care Act is not in itself an exclusion criterion)
Exclusion Criteria:
- Dementia
- Intellectual disability
- Severe somatic comorbidity with life expectancy <6 months
- Ongoing mania / mixed-state
- Complex problems that make APS impossible or inappropriate
- Expected discharge within 3 days
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Acute psychological sleep stabilization
The basis of the treatment is CBT-I adapted to a short version performed by trained staff (nurses or mental health care assistants) together with a psychologist. The manuals are designed to be read by patients and staff together and each treatment manual covers a specific topic. The focus of the treatment is behavioral changes and central manuals are stimulus control and scheduled sleep and sleep compression (if needed). |
See above (arm description) |
|
Comparateur actif: Sleep hygiene education
The control treatment is delivered through structured manuals which patients work through together with the staff. The manuals cover sleep hindering factors (eg coffee, nicotine), sleep promoting factors (eg physical activity during the day, relaxation, blinds), sleep aids (for example, weight blanket, calm music). |
See above (arm description) |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Insomnia Severity Index
Délai: 2 weeks post randomization (secondary timepoints include day 4, 7, 10 and week 4 and 12)
|
A self-report measure of insomnia symptoms. 7-item, self-rated questionnaire measuring insomnia severity. Total score 0-28, higher score indicates more severe sleep problems. |
2 weeks post randomization (secondary timepoints include day 4, 7, 10 and week 4 and 12)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Patient Health Questionnaire (PHQ-9)
Délai: Day 4, 7, 10 14 and week 4 and 12 post randomisation
|
Self-reported depressive symptoms. PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression. Total score 0-27, higher score indicates more severe depressive symptoms. |
Day 4, 7, 10 14 and week 4 and 12 post randomisation
|
|
Generalised Anxiety Disorder 7-item scale (GAD-7)
Délai: Day 4, 7, 10 14 and week 4 and 12 post randomisation
|
Self-reported anxiety symptoms. A seven-item instrument that is used to measure or assess the severity of generalised anxiety disorder/symptoms. Total score 0-27. Higher scores indicative of more severe problem. |
Day 4, 7, 10 14 and week 4 and 12 post randomisation
|
|
European Quality of Life 5 Dimensions scale (EQ-5D)
Délai: Week 2, 4 and 12 post randomisation
|
Self-reported quality of life. An instrument which evaluates the generic quality of life developed in Europe and widely used. The scale comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. |
Week 2, 4 and 12 post randomisation
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Sleep Diary
Délai: 0-14 days post randomisation
|
Participants will report their bedtime, risetime, amount of sleep daily using a simplified version of a sleep diary. We will look at total sleep time, sleep efficiency, and timing of sleep. |
0-14 days post randomisation
|
|
Actigraphy
Délai: 0-14 days post randomisation
|
An actigraph is placed on the participant's arm for 2 weeks. It measures participants' arm-movements. An algorithm can be used to estimate sleep from movement data.Data from actigraphs will be reported and analysed |
0-14 days post randomisation
|
|
Side effects of treatment
Délai: Day 7 and 14 post randomisation
|
Patients will be asked to report any side-effects of the treatment with an open question |
Day 7 and 14 post randomisation
|
|
Treatment Credibility Scale
Délai: Day 4 post randomisation
|
A five-item version of Credibility/Expectancy Questionnaire, total score ranging from 0-50. Higher scores indicative of higher credibility. |
Day 4 post randomisation
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Sandra Tamm, Karolinska Institutet
- Chercheur principal: Susanna Jernelöv, Karolinska Institutet
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- Dnr 2023-02223-01
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Individual data will not be shared
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .